Abstract: OBJECTIVE To investigate the status of liver injury and the use of hepatoprotective drugs in patients with colorectal malignant tumors, analyze the related factors that may affect liver injury, evaluate the characteristics of liver injury caused by different chemotherapy regimens and the normative use of hepatoprotective drugs. METHODS A retrospective analysis was performed on 200 patients with colorectal cancer who received chemotherapy during the period from June 1, 2017 to May 31, 2018. The patient's personal information, chemotherapy regimen, and use of hepatoprotective drugs were recorded. Analyze the relevant factors and evaluate the rationality of the use of liver-protecting drugs. RESULTS Factors related to liver injury were analyzed by gender, age, body surface area, tumor type, tumor stage, course of treatment, alcohol consumption, and adverse reactions in chemotherapy. It was found that tumor staging, period of treatment and moderate to severe gastrointestinal reactions in chemotherapy were associated with liver injury. The rationality of hepatoprotective drugs was evaluated comprehensively from the following aspects:indications of administration, repeated administration, timing of administration, course of treatment and contraindications of administration. The 140 of 155 patients who had used hepatoprotective drugs were in accordance with the instructions or guidelines for the use of hepatoprotective drugs. CONCLUSION There is no significant difference in the degree of liver injury between different chemotherapy regimens. Tumor staging and period of treatment are the influencing factors of liver injury. In addition, the use of hepatoprotective drugs should be more standardized in clinic.